Themis Medicare Ltd banner

Themis Medicare Ltd
NSE:THEMISMED

Watchlist Manager
Themis Medicare Ltd Logo
Themis Medicare Ltd
NSE:THEMISMED
Watchlist
Price: 96.42 INR 0.79% Market Closed
Market Cap: ₹8.9B

THEMISMED's latest stock split occurred on Oct 10, 2023

The company executed a 10-for-1 stock split, meaning that for every share held, investors received 10 new shares.

Before the split, THEMISMED traded at 184.25 per share. Afterward, the share price was about 180.6.

The adjusted shares began trading on Oct 10, 2023. This was the only stock split in THEMISMED's history.

Last Splits:
Oct 10, 2023
10-for-1
Pre-Split Price
184.25 184.25
Post-Split Price
180.6
Before
After
Last Splits:
Oct 10, 2023
10-for-1

Themis Medicare Ltd
Stock Splits History

THEMISMED Stock Splits Timeline
Oct 10, 2023
Oct 10, 2023
Split 10-for-1
x10
Pre-Split Price
184.25 184.25
Post-Split Price
180.6
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Cue Biopharma Inc
NASDAQ:CUE
1-for-30
/30
0.5542 16.626 USD 17.695 17.695 USD
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
E
ESGL Holdings Ltd
NASDAQ:ESGL
1-for-3
/3
2.35 7.05 USD 2.93 2.93 USD
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Apr 24, 2026
L
La Comer SAB de CV
OTC:LCMRF
115-for-114
x1.0087719298246
2.4715 2.4341 USD 2.45 2.45 USD
Load More

Themis Medicare Ltd
Glance View

Market Cap
8.9B INR
Industry
Pharmaceuticals

Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-04-02. The firm is focused on the formulation and active pharmaceutical ingredients (API) activity. Its product category includes star products, differential products, and APIs. Its star products include OD-LM (Levocetrizine 5 mg + Montelukast 10 mg), Medzol (Midazolam hydrochloride 1 ml, 5ml and 10 ml), Cisatra (Cisatracurium 2 mg/ml), and Aquadol (Diclofenac sodium 75mg/ml). Its differential products include Enterofizz-EL (Bacillus clausii + Electrolytes) and Etojet (Etoricoxib 90mg/ml). Its APIs products include Simvastatin, Ketamine Hcl, and Isosorbide Di Methyl Ether (THEMISOL).The Company’s manufacturing locations in India are situated at Vapi, Haridwar and Hyderabad. The firm markets in over 44 countries. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).

THEMISMED Intrinsic Value
92.75 INR
Overvaluation 4%
Intrinsic Value
Price ₹96.42
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett